| S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial 1999 · AdoMet · Patients with alcoholic liver cirrhosis, Child classes A, B, or C | 1.2 g | 2 years | 62 |
| S-Adenosylmethionine (SAMe) monotherapy for depression: an 8-week double-blind, randomised, controlled trial 2020 · SAMe · Adults with DSM-5 major depressive disorder and mild-to-moderate depressive symptoms (MADRS score 14–25), not currently taking antidepressants | 800 mg | 8 weeks | — |
| S-adenosyl-methionine and betaine improve early virological response in chronic hepatitis C patients with previous nonresponse 2010 · Group B · Adults aged 18–65 with chronic hepatitis C and previous nonresponse to interferon/ribavirin combination treatment | 1.2 g | 48 weeks | 17 |
| S-adenosyl-methionine and betaine improve early virological response in chronic hepatitis C patients with previous nonresponse 2010 · Group A · Adults aged 18–65 with chronic hepatitis C and previous nonresponse to interferon/ribavirin combination treatment | 1.2 g | 49 weeks | 16 |
| Efficacy and tolerability of oral and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies 2002 · Oral SAMe (MC3) · Patients with major depressive episode and baseline 21-item HAM-D score ≥18 | 1.6 g | 6 weeks | 143 |
| Comparative clinical trial of S-adenosylmethionine versus nabumetone for the treatment of knee osteoarthritis: an 8-week, multicenter, randomized, double-blind, double-dummy, Phase IV study in Korean patients 2009 · SAMe 400 mg TID · Korean adults over 18 years with knee osteoarthritis | 1.2 g | 8 weeks | 67 |
| S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. [ISRCTN36233495] 2004 · SAMe treatment phase · Adults aged 40 or older with osteoarthritis of the knee | 1.2 g | 8 weeks | 56 |
| S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial 2010 · adjunctive SAMe · Serotonin reuptake inhibitor nonresponders with major depressive disorder | 1.6 g | 6 weeks | — |
| Dose increase of S-Adenosyl-Methionine and escitalopram in a randomized clinical trial for major depressive disorder 2020 · SAMe increased-dose group (week 7–12; nonresponders) · Adults aged 18–80 of both sexes with major depressive disorder who had not responded to the initial treatment dose at week 6 | 3.2 g | 6 weeks | — |
| Dose increase of S-Adenosyl-Methionine and escitalopram in a randomized clinical trial for major depressive disorder 2020 · SAMe unchanged-dose group (week 7–12; responders) · Adults aged 18–80 of both sexes with major depressive disorder who responded to the initial treatment dose by week 6 | 1.6 g | 6 weeks | — |
| Double-blind, placebo-controlled study of S-adenosyl-L-methionine in depressed postmenopausal women 1993 · SAMe · Women aged 45–59 with DSM-III-R major depressive disorder or dysthymia, 6–36 months after natural menopause or hysterectomy | 1.6 g | 30 days | — |
| Oral Administration of S-Adenosylmethionine (SAMe) and Lactobacillus Plantarum HEAL9 Improves the Mild-To-Moderate Symptoms of Depression: A Randomized, Double-Blind, Placebo-Controlled Study 2020 · SAMe plus L. plantarum HEAL9 · Adults aged 18–60 with subthreshold or mild-to-moderate depression | 200 mg | 6 weeks | 46 |
| Efficacy of a food supplement based on S-adenosyl methionine and probiotic strains in subjects with subthreshold depression and mild-to-moderate depression: A monocentric, randomized, cross-over, double-blind, placebo-controlled clinical trial 2022 · Food supplement · People with subthreshold depression or mild-to-moderate depression | 200 mg | 90 days | — |
| A randomized, double blind, placebo controlled trial of intravenous loading with S-adenosylmethionine (SAM) followed by oral SAM therapy in patients with knee osteoarthritis 1994 · S-adenosylmethionine (SAM) · Patients with symptomatic knee osteoarthritis; age and sex not specified | 600 mg | 4 weeks | — |
| A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia 2010 · NF group, 3-month blinded trial · Community-dwelling adults aged 18–86 years, both sexes, without dementia or clinical memory difficulties | 400 mg | 90 days | 59 |
| A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia 2010 · Open-label NF group, separate 6-month trial · Community-dwelling adults, both sexes, without dementia or clinical memory difficulties | 400 mg | 26 weeks | 38 |
| A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia 2010 · NF group, 2-week blinded trial · Community-dwelling adults, both sexes, without dementia or clinical memory difficulties | 400 mg | 2 weeks | — |
| Dietary supplement S-adenosyl-L-methionine (AdoMet) effects on plasma homocysteine levels in healthy human subjects: a double-blind, placebo-controlled, randomized clinical trial 2009 · AdoMet · Healthy human volunteers | 800 mg | 4 weeks | — |
| Bioavailability of S-adenosyl methionine and impact on response in a randomized, double-blind, placebo-controlled trial in major depressive disorder 2012 · SAMe arm · Adults with major depressive disorder who had not responded to serotonin-reuptake inhibitors; mean age 55 years, 50% female | 1.6 g | 6 weeks | 20 |
| A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis 2004 · S-adenosyl-l-methionine · Women at less than 36 weeks of gestation with severe gestational cholestasis | 1 g | — | 22 |
| S-adenosyl-L-methionine treatment for alcoholic liver disease: a double-blinded, randomized, placebo-controlled trial 2011 · SAM group · Adults with alcoholic liver disease and a history of chronic alcohol abuse | 1.2 g | 24 weeks | 18 |
| Oral S-adenosylmethionine in the symptomatic treatment of intrahepatic cholestasis. A double-blind, placebo-controlled study 1990 · S-adenosylmethionine group · Adults with chronic liver disease (26% chronic active hepatitis, 68% cirrhosis, 6% primary biliary cirrhosis) and elevated serum bilirubin and alkaline phosphatase | 1.6 g | — | — |